How Making GLP-1s Available Over the Counter Can Unlock Their Full Potential

reason.com/2025/05/31/unlocking-the-full-potential-of-glp-1s

When the Food and Drug Administration (FDA) approved Byetta (exenatide) in 2005, doctors thought it was just approving the first glucagon-like peptide-1 (GLP-1) agonist to treat Type 2 diabetes. But this new drug class had the potential to treat a host of other problems.
GLP-1 agonists…

This story appeared on reason.com, 2025-05-31 10:00:43.
The Entire Business World on a Single Page. Free to Use →